Consensus BioArctic AB

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 02:15:30 11/07/2025 pm IST			5-day change	1st Jan Change
188.50 ^SEK	-0.63%		+3.01%	-5.66%

17/06	Lannebo Sverige Plus increased by 4.3 percent in May – rising profitability at Elekta	FW
13/06	BioArctic to Advance Parkinson's Disease Drug Trial After Positive Safety Review	MT

Evolution of the Average Target: BioArctic AB

Evolution of the Target Price: BioArctic AB

Changes in Analyst Recommendations: BioArctic AB

10de62417eee11966558.01yF7BsnvIt0HlzYcvC7I5IQApdcro82M72NTjxtrT4.mCvRjnoRy9InfSbvK8Hie8Fqc64e9L5vZOfJOVMo23KrPt-jdnT_si1NKw~3ff3cf9e2dc977ecc42d2c50efd402a8

Analysts' recommendations: BioArctic AB

Goldman Sachs lowers target price for Bioarctic to SEK 237 (267), reiterates buy recommendation - BN	02/06	FW
Carnegie lowers target price for Bioarctic to SEK 300 (360), reiterates buy recommendation - BN	07/05	FW
Goldman Sachs lowers target price for Bioarctic to SEK 267 (308), reiterates Buy - BN	22/04	FW
RBC lowers target price for Bioarctic to SEK 280 (340), reiterates outperform - BN	16/04	FW
RX Securities lowers target price for Bioarctic to SEK 310 (360), reiterates Buy - BN	25/03	FW
Goldman Sachs lowers target price for Bioarctic to SEK 308 (316), reiterates Buy - BN	18/02	FW
Carnegie raises target price for Bioarctic to SEK 360 (350), reiterates Buy - BN	17/02	FW
RBC analysts fear Bioarctic's drug Leqembi could be delayed in EU - BN	31/01	FW
Carnegie raises target price for Bioarctic to SEK 350 (318), reiterates Buy - BN	28/01	FW
Goldman Sachs raises target price for Bioarctic to SEK 316 (292), reiterates Buy - BN	24/01	FW
Analysts consider Bioarctic's billion-dollar deal a great deal - Di	19/12	FW
RX Securities raises target price for Bioarctic to SEK 360 (330), reiterates Buy - BN	19/12	FW
Di lists five companies to watch in 2025	18/12	FW
Biogen downgraded to Hold by Stifel - slower progress than expected	17/12	FW
Di: These seven hard-to-get stocks to buy according to the experts	29/11	FW
Goldman Sachs raises target price for Bioarctic to SEK 292 (286), reiterates Buy - BN	25/11	FW
RBC raises target price for Bioarctic to SEK 340 (290), reiterates outperform - BN	20/11	FW
Redeye raises motivated value for Bioarctic to SEK 310 (275)	18/11	FW
DNB raises target price for Bioarctic to SEK 350 (270), reiterates Buy - BN	18/11	FW
RX Securities raises target price for Bioarctic to SEK 330 (270), reiterates Buy - BN	15/11	FW
Main reason for Eisai's lowered forecast for Leqembi is infusion capacity - Redeye	08/11	FW
RX Securities lowers target price for Bioarctic to SEK 270 (290), reiterates Buy - BN	08/11	FW
Carnegie lowers target price for Bioarctic to SEK 318 (340), reiterates Buy - BN	05/11	FW
Bioarctic turns upwards after yesterday's fall - RBC sees continued potential	17/24/17	FW
Today's stock recommendations at a glance	17/24/17	FW

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus (Composite)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
	BIOARCTIC AB					+52.56%
	LONZA GROUP AG					+15.58%
	BEONE MEDICINES LTD.					+30.61%
	CELLTRION, INC.					+20.93%
	IQVIA HOLDINGS INC.					+15.19%
	EUROFINS SCIENTIFIC SE					-1.47%
	ICON PUBLIC LIMITED COMPANY					+15.74%
	ASCENDIS PHARMA A/S					+33.1%
	QIAGEN N.V.					+3.85%
	TEMPUS AI, INC.					+11.91%
	Average					+19.80%
	Weighted average by Cap.					+17.98%